X

Trial Profile

Partnership for Research on Ebola VACcinations (PREVAC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary) ; RVSV-S-GP/VP40 vaccine (Primary)
Indications Ebola virus infections
Focus Pharmacodynamics
Acronyms PREVAC

Most Recent Events

26 Jun 2024 Status changed from active, no longer recruiting to completed.
15 Nov 2023 Results accessing immunogenicity and vaccine shedding after 1 or 2 doses of Ebola vaccine in prevention of Ebola-virus-infections, published in the Clinical Infectious Diseases.
14 Dec 2022 Results evaluating the safety and immune responses of three vaccine regimens against Zaire Ebola virus disease, published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com